Search results (1320)
« Back to PublicationsIL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma.
Taylor CA. et al, (2022), Nat Med
Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy.
Schnegg-Kaufmann AS. et al, (2022), Blood
Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies.
Moreno V. et al, (2022), Cancer Immunol Immunother, 71, 2985 - 2998
CNL and aCML should be considered as single entity based on molecular profiles and outcomes.
Carreño-Tarragona G. et al, (2022), Blood Adv
Human bone marrow organoids for disease modelling, discovery and validation of therapeutic targets in hematological malignancies.
Khan AO. et al, (2022), Cancer Discov
Single-cell methods in myeloproliferative neoplasms - old questions, new technologies.
O'Sullivan JM. et al, (2022), Blood
Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway.
Zhang X-Y. and Collins GP., (2022), Curr Oncol Rep, 24, 1477 - 1488
First-in-human phase I/II, open-label study of the anti-OX40 agonist INCAGN01949 in patients with advanced solid tumors.
Davis EJ. et al, (2022), J Immunother Cancer, 10
HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL).
Carlo-Stella C. et al, (2022), Clin Lymphoma Myeloma Leuk, 22 Suppl 2
MPN-238 Single-Cell RNA Profiling of Myelofibrosis Patients Reveals Pelabresib-Induced Decrease of Megakaryocytic Progenitors and Normalization of CD4+ T Cells in Peripheral Blood.
Zavidij O. et al, (2022), Clin Lymphoma Myeloma Leuk, 22 Suppl 2, S331 - S332
A qualitative exploration of digital medicines information usage: Insights from an evaluation of the BNF
Blagden S. et al, (2022), Health Policy and Technology, 11
How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?
Horgan D. et al, (2022), Healthcare (Basel), 10
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.
Larkin J. et al, (2022), Eur J Cancer, 173, 285 - 296
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
Harrison CN. et al, (2022), Future Oncol
A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience.
Kuhnl A. et al, (2022), Br J Haematol, 198, 492 - 502
CD34+CD19-CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies.
Bueno C. et al, (2022), Blood, 140, 38 - 44
Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity.
Henriksen PA. et al, (2022), Circ Heart Fail, 15